Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Completed · Phase 2

Conditions studied: Essential Thrombocythemia

In brief

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, Bomedemstat (MK-3543, formerly called IMG-7289), in patients with essential thrombocythemia. This study investigates the following: * The safety and tolerability of Bomedemstat * The pharmacodynamic effect of Bomedemstat

Key facts

Study ID

NCT04254978

Run by

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

People needed

73

Starts

2020-09-08

Expected to finish

2023-03-23

Last updated by the study team

2026-05-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms.
• Requires treatment in order to lower platelet count based on patient age over 60 or history of thrombosis.
• Have failed at least one standard therapy
• Must have discontinued ET therapy at least 1 week (4 weeks for interferon) prior to study drug initiation.

You may not qualify if…

• Has undergone major surgery ≤4 weeks prior to starting study drug or has not recovered from side effects of such surgery.
• Unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1).
• Uncontrolled active infection.
• Current use of prohibited medications
• Known HIV infection or active Hepatitis B or Hepatitis C virus infection
• Other hematologic/biochemistry requirements, as per protocol
• Use of investigational agent within last 14 days
• Pregnant or lactating females

Where it is running

• Local Institution — Jacksonville, Florida, United States
• Local Institution — Ann Arbor, Michigan, United States
• Local Institution — New York, New York, United States
• Local Institution — Durham, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Local Institution — Pittsburgh, Pennsylvania, United States
• Local Institution — Seattle, Washington, United States
• Local Institution — Herston, Brisbane, Australia
• Local Institution — Camperdown, New South Wales, Australia
• Local Institution — St Leonards, New South Wales, Australia
• Local Institution — Southport, Queensland, Australia
• Royal Adelaide Hospital — Adelaide, South Australia, Australia
• Local Institution — Clayton, Victoria, Australia
• Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ) — Essen, Germany
• Local Institution — Jena, Germany
• Local Institution — Hong Kong, Hong Kong
• Local Institution — Alessandria, Italy
• Local Institution — Bologna, Italy
• CRIMM; Centro Ricerca e Innovazione delle Malattia Mieloproliferative, Azienda ospedaliera Universitaria Careggi — Florence, Italy
• Local Institution — Varese, Italy
• Local Institution — Auckland, New Zealand
• Middlemore Hospital — Auckland, New Zealand
• Local Institution — London, United Kingdom
• Guys and St Thomas Hospital — London, United Kingdom
• Local Institution — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.